Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Smolle, MA; Schaffler, A; Leithner, A; Van, Praag, VM; Bergovec, M; Szkandera, J; Liegl-Atzwanger, B; Niethard, M; Tunn, PU; Van, De, Sande, M; Andreou, D.
Incidence, treatment and outcome of abdominal metastases in extremity soft tissue sarcoma: Results from a multi-centre study.
J Surg Oncol. 2020; 121(4):605-611 Doi: 10.1002/jso.25856 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG


Führende Autor*innen der Med Uni Graz
Leithner Andreas
Smolle Maria Anna
Co-Autor*innen der Med Uni Graz
Andreou Dimosthenis
Bergovec Marko
Liegl-Atzwanger Bernadette
Szkandera Joanna

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

BACKGROUND AND OBJECTIVES: Abdominal metastases (AM) from soft tissue sarcoma (STS) are rare and prognosis is poor. The aims of the study were to (a) identify risk factors for the development of AM and to (b) investigate the outcome of AM-patients. METHODS: Seven-hundred-sixty-nine STS-patients with localised disease at diagnosis treated at three tumour centres (2000-2016) were retrospectively included (409 males; mean age, 55.6 years [range, 8-96 years]; median follow-up, 4.1 years [interquartile-range, 2.5-6.6 years]). RESULTS: Two-hundred-two patients (26.3%) developed secondary metastases, and 24 of them AM (3.1%). Ten patients developed first AM (FAM) after a mean of 2.4 years and 14 patients late AM (LAM, after being diagnosed with metastases to other sites) after a mean of 2.0 years. Patients with liposarcoma had a significantly higher risk of developing AM (P = .007), irrespective of grading. There was no difference in post-metastasis-survival (PMS) between patients with AM at any time point and those with metastases to other sites (P = .585). Patients with LAM or FAM showed no difference in post-abdominal-metastasis-survival (P = .884). CONCLUSIONS: Survival in patients with AM is poor, irrespective of whether they develop secondarily to other metastases or not. Patients at high-risk of AM (ie, liposarcoma) may be followed-up regularly by abdominal-ultrasound/CT.
Find related publications in this database (using NLM MeSH Indexing)
Abdominal Neoplasms - secondary, therapy
Adolescent - administration & dosage
Adult - administration & dosage
Aged - administration & dosage
Aged, 80 and over - administration & dosage
Child - administration & dosage
Extremities - pathology
Female - administration & dosage
Humans - administration & dosage
Incidence - administration & dosage
Male - administration & dosage
Middle Aged - administration & dosage
Retrospective Studies - administration & dosage
Risk Factors - administration & dosage
Sarcoma - pathology, therapy
Young Adult - administration & dosage

Find related publications in this database (Keywords)
abdominal metastasis
soft tissue sarcoma
© Med Uni Graz Impressum